Physician profile
Ly DO
NPI 1376706929
$8,524.50
in general payments reported to CMS, 2019-2025
50 companies · $1,645 in 2025
The $1,645 reported for 2025 was more than what 88% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,075 · 2020: $490 · 2021: $1,060 · 2022: $1,758 · 2023: $1,279 · 2024: $1,217 · 2025: $1,645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,942 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,942.39 |
| Education | $199.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,294.61 | 2019-2025 | Imfinzi, Enhertu, Tagrisso |
| Janssen Biotech, INC. | $825.02 | 2019-2025 | Darzalex, Talvey, Tecvayli |
| Merck Sharp & Dohme LLC | $687.71 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Novartis Pharmaceuticals Corporation | $652.31 | 2019-2025 | |
| Lilly USA, LLC | $495.86 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| E.R. Squibb & Sons, L.L.C. | $407.71 | 2019-2023 | Opdivo |
| Pfizer INC. | $364.85 | 2019-2025 | |
| Astellas Pharma US INC | $321.09 | 2019-2025 | Xtandi, Padcev |
| Progenics Pharmaceuticals, INC. | $280.03 | 2023-2025 | Pylarify |
| Bayer Healthcare Pharmaceuticals INC. | $214.11 | 2019-2025 | |
| Seagen INC. | $192.39 | 2019-2023 | Adcetris |
| Glaxosmithkline, LLC. | $186.20 | 2020-2025 | Ojjaara |
| Amgen INC. | $160.92 | 2019-2023 | Nplate, Vectibix |
| Daiichi Sankyo INC. | $149.01 | 2023-2025 | Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $144.56 | 2020-2025 | Fruzaqla, Advate |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ly DO listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.